We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · April 02, 2020

There Is No Evidence to Abandon RAS Blockers During the COVID-19 Pandemic

Hypertension

 

Additional Info

Disclosure statements are available on the authors' profiles:

Hypertension
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
Hypertension 2020 Mar 25;[EPub Ahead of Print], AHJ Danser, M Epstein, D Batlle

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading